Clinical Trial Update: Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating decitabine as a sensitizer to carboplatin in platinum-resistant recurrent ovarian cancer has completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dacogen (decitabine)

Snippet

Sponsor: Indiana University | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-25